Начало・Списък с акции・TransMedics Group Inc

TransMedics Group Inc

Затворен

СекторЗдравеопазване

80.5 -1.38

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

78.31

Максимум

81.92

Ключови измерители
By Trading Economics
Приходи	-98M 7.3M
Продажби	13M 174M
P/E Средно за сектора	16.998 64.641
EPS	0.3
Марж на печалбата	4.206
Служители	898
EBITDA	-4.9M 28M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+41.02% upside

Дивиденти
By Acuity
Следващи печалби	4.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-786M 2.6B
Предишно отваряне	81.88
Предишно затваряне	80.5

Настроения в новините

By Acuity

65%

35%

289 / 340 Класиране в Healthcare

TransMedics Group Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.08.2026 г., 19:51 ч. UTC

Social Media

News

TransMedics Group Inc. shares are rising, despite an analyst downgrade to a $106 price target from $142, amid positive social media discussions.

30.07.2026 г., 19:03 ч. UTC

Transmedics Group Inc shares are lower during Thursday's session, with no specific news identified. Broader market uncertainty may be influencing the decline.

29.07.2026 г., 23:36 ч. UTC

Transmedics Group Inc. shares are lower in after-market trading, reflecting broader market volatility amid rising interest rates and geopolitical tensions.

28.07.2026 г., 19:46 ч. UTC

Transmedics Group Inc shares are higher today, advancing since Monday. The stock peaked earlier but pulled back from a session high.

27.07.2026 г., 15:16 ч. UTC

Social Media

News

Transmedics Group Inc is higher today amid social media discussions on its undervaluation and expectations for significant profit by 2028.

24.07.2026 г., 20:02 ч. UTC

Social Media

Transmedics Group Inc gains amid positive feedback from Jefferies on its technology and growth prospects, aligning with strength in the Health Care Equipment sector.

22.07.2026 г., 19:46 ч. UTC

Transmedics Group Inc shares are lower today, reflecting ongoing declines. The stock's volatility coincides with rising crude oil prices amid geopolitical tensions.

21.07.2026 г., 14:36 ч. UTC

Social Media

Transmedics Group's shares are higher today following the first lung transplant using its OCS warm-perfusion device, enhancing organ preservation and clinical outcomes.

20.07.2026 г., 12:26 ч. UTC

Social Media

TransMedics Group Inc shares are higher in pre-market trading amid strong operational growth, with flights exceeding 36 per day and projected revenue of $3 billion by 2032.

Сравнение с други в отрасъла

Ценова промяна

TransMedics Group Inc Прогноза

Ценова цел

By TipRanks

41.02% нагоре

12-месечна прогноза

Среден 115 USD 41.02%

Висок 175 USD

Нисък 80 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за TransMedics Group Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на TransMedics Group Inc през последните 3 месеца.

Настроение

By Acuity

289 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.